Common-Size Income Statement
Quarterly Data
Based on: 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31), 10-K (reporting date: 2021-12-31), 10-Q (reporting date: 2021-09-30), 10-Q (reporting date: 2021-06-30), 10-Q (reporting date: 2021-03-31), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-30), 10-Q (reporting date: 2020-06-30), 10-Q (reporting date: 2020-03-31), 10-K (reporting date: 2019-12-31), 10-Q (reporting date: 2019-09-30), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31).
Income statement item | Description | The company |
---|---|---|
Operating income | The net result for the period of deducting operating expenses from operating revenues. | Amgen Inc. operating income as a percentage of product sales decreased from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024. |
Income (loss) before income taxes | Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. | Amgen Inc. income (loss) before income taxes as a percentage of product sales decreased from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024. |
Net income (loss) | The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. | Amgen Inc. net income (loss) as a percentage of product sales decreased from Q3 2023 to Q4 2023 and from Q4 2023 to Q1 2024. |